Does Humana Cover Tirosint? Formulary, Prior Auth, and Appeal Guide

What Is Tirosint and Why Do Some Patients Need It?

Tirosint is an FDA-approved levothyroxine formulation delivered in a liquid-filled gel capsule, containing no dyes, gluten, lactose, or acacia. The FDA approved the original gel-cap formulation in 2010 and the liquid solution (Tirosint-SOL) in 2017. Both formulations matter clinically because standard levothyroxine tablets depend on acidic gastric conditions for absorption, and many patients absorb them poorly.

Vita et al. (2014, Endocrine, N=56) demonstrated that patients with autoimmune gastritis who switched from levothyroxine tablets to the liquid formulation reached target TSH levels significantly faster, with TSH normalization occurring in a median of 30 days compared to persistent elevation on tablets [1]. That absorption advantage is the clinical argument prescribers use when requesting Tirosint through Humana's prior authorization process.

The American Thyroid Association guidelines note that levothyroxine bioavailability ranges from 40% to 80% with standard tablets and is affected by proton pump inhibitor use, calcium supplements, coffee, and conditions including celiac disease and bariatric surgery [2]. Patients with any of these comorbidities may have a legitimate medical need for the gel-cap formulation.

Standard levothyroxine tablets are listed by the FDA as a narrow therapeutic index drug [3]. Small bioavailability fluctuations translate directly into clinical hypothyroidism or thyrotoxicosis, which is why physicians argue that switching between formulations is not always trivial.

Tirosint's FDA prescribing information documents that the gel-capsule formulation produced equivalent thyroid hormone levels to standard tablets in healthy volunteers but superior absorption in subjects with achlorhydria [4]. This pharmacokinetic distinction is the central evidence base clinicians submit to insurers.

How Humana's Formulary Classifies Tirosint

Humana places Tirosint on a Tier 3 or Tier 4 non-preferred brand position on most commercial formularies, which means member cost-sharing is higher than for generic levothyroxine. Generic levothyroxine tablets (Synthroid equivalents) sit at Tier 1 or Tier 2, costing members $0, $15/month on many Humana commercial plans versus $60, $120+ for Tirosint after deductible.

Formulary placement changes annually. The authoritative source is Humana's online Drug List tool at humana.com/pharmacy/drug-list, and members should verify their specific plan's 2025 formulary because mid-year tier changes are permitted for non-protected drug classes.

The FDA classifies levothyroxine as a narrow therapeutic index drug, which the agency defines as a drug where small differences in dose or blood concentration may lead to serious therapeutic failures or adverse reactions [3]. Several professional organizations have cited this classification to argue against automatic substitution between levothyroxine formulations [5].

Humana Medicare Advantage plans operate under CMS formulary rules that generally do not require coverage of brand-name drugs when a generic equivalent exists. Because generic levothyroxine tablets are widely available at low cost, many Humana MA plans place Tirosint on a non-formulary status, meaning it is not covered at all under standard benefits [6].

The table below summarizes typical Tirosint coverage status across Humana plan types. Actual benefits differ by specific plan ID and state, so members must verify through Humana's plan documents.

| Plan Type | Typical Tier | PA Required | Step Therapy | |---|---|---|---| | Humana Commercial (employer) | Tier 3, 4 | Yes | Yes (generic LT4 first) | | Humana Individual Marketplace | Tier 3, 4 | Yes | Yes | | Humana Medicare Advantage | Non-formulary on many plans | N/A (excluded) | N/A | | Humana Part D stand-alone PDP | Non-formulary on most plans | N/A | N/A |

Prior Authorization Criteria Humana Typically Requires

Humana's commercial prior authorization for Tirosint generally requires documentation of at least one of the following clinical circumstances: persistent TSH elevation despite adequate doses of generic levothyroxine tablets taken on an empty stomach, a confirmed diagnosis causing malabsorption (such as celiac disease, short bowel syndrome, or post-bariatric surgery status), concurrent use of medications that significantly impair levothyroxine absorption (including proton pump inhibitors, cholestyramine, or high-dose calcium carbonate), or a documented allergy or intolerance to an inactive ingredient in tablet formulations.

The prior authorization request must come from the prescribing physician and should include current TSH and free T4 lab values, a detailed medication history showing the trial of generic levothyroxine at an appropriate dose and duration, and ICD-10 codes supporting the underlying indication. E03.9 (hypothyroidism, unspecified) is the base code; adding E03.8 (other specified hypothyroidism) or K90.0 (celiac disease) strengthens the clinical narrative.

The Endocrine Society's Clinical Practice Guideline on hypothyroidism states that clinicians should consider alternative levothyroxine formulations when patients have persistent TSH abnormality despite confirmed adherence and appropriate dosing on standard tablets [7]. That language is directly usable as supporting text in a PA submission.

Humana's standard PA review timeline under commercial plans is 3 business days for non-urgent requests and 1 business day for urgent requests, per CMS and state insurance regulations [8]. If Humana issues a denial, the denial letter must include the specific clinical reason and information about the appeal process.

TSH target ranges also matter. The American Association of Clinical Endocrinology recommends a TSH target of 0.5, 2.5 mIU/L for most treated hypothyroid patients [9]. A documented TSH above this range despite six to eight weeks of generic tablet therapy is strong evidence for the PA submission.

Step Therapy: What Humana Requires You to Try First

Step therapy on most Humana commercial plans means the member must try and fail at least one generic levothyroxine tablet formulation before Tirosint is approved. "Fail" is defined by Humana's medical criteria as either a persistent TSH outside the therapeutic target range or a documented intolerance.

A trial typically needs to be at least 6 weeks at a stable dose, because the half-life of levothyroxine is approximately 7 days and TSH requires 4 to 6 weeks to reach a new steady state after a dose change [4]. Lab values drawn before 6 weeks do not accurately reflect the drug's effect at that dose.

The FDA has received citizen petitions arguing against automatic substitution of levothyroxine formulations precisely because of narrow therapeutic index concerns [3]. Some states have enacted laws restricting pharmacist substitution of levothyroxine without prescriber consent, which also supports the argument that formulations are not clinically interchangeable for all patients [10].

Patients who have already completed step therapy on a previous Humana plan or with a prior insurer can submit those medical records as documentation, potentially allowing Humana to waive the step therapy requirement. This is called a step therapy override or exception, and it is a legal right under many state laws and under the 21st Century Cures Act for employer plans [11].

The 21st Century Cures Act, signed into law in 2016, requires employer-sponsored health plans subject to ERISA to have a clear step therapy exception process. Humana's commercial plans follow this requirement and must respond to exception requests within 3 business days (or 1 business day for urgent cases) [11].

How to Appeal a Humana Denial of Tirosint

A Humana denial is not the end of the process. For commercial plans, the internal appeal process has two levels: a first-level internal appeal reviewed by a Humana clinician who was not involved in the original decision, and a second-level appeal or an expedited external review through an independent review organization (IRO) accredited by URAC or NCQA [12].

For Medicare Advantage members, the appeals pathway is more structured. The first step is a Humana organization determination, then a reconsideration by Humana, then an appeal to MAXIMUS Federal Services (the independent Medicare review contractor), then a hearing before an Administrative Law Judge, then a Medicare Appeals Council review, and finally federal district court [6].

Success rates improve substantially when appeals include peer-reviewed literature. Vita et al. (2014) [1] and the FDA prescribing information for Tirosint [4] are the two most commonly cited documents. Adding a letter of medical necessity written by a board-certified endocrinologist significantly increases approval odds at the IRO level.

The appeal letter should directly address the specific denial reason Humana cited. If the denial was "generic equivalent available," the response should include the FDA's narrow therapeutic index classification [3] and lab evidence that the generic failed. If the denial was "not medically necessary," cite the Endocrine Society guideline language [7] and the patient's TSH trend on generic tablets.

For MA denials, MAXIMUS must issue a decision within 72 hours for expedited appeals and within 7 calendar days for standard appeals, per CMS regulations [6]. Approximately 40% of Medicare drug coverage appeals that reach independent review are overturned in favor of the member, based on CMS Medicare Appeals data [13].

State insurance commissioners can also accept complaints about commercial plan denials, and many states require plans to cover FDA-approved drugs when a treating physician documents medical necessity. Filing a complaint with the state commissioner in parallel with an internal appeal sometimes accelerates the insurer's review.

Does Humana Cover Tirosint for Weight Loss?

No. Tirosint is not FDA-approved for weight loss, and prescribing levothyroxine for weight loss in patients with normal thyroid function is not supported by clinical evidence [4]. CMS explicitly prohibits Medicare Advantage plans from covering drugs prescribed primarily for weight loss under 42 CFR 411.46 [6].

On commercial plans, a prescription for Tirosint with a weight-loss diagnosis code (such as E66.09) would be rejected at the pharmacy claims level regardless of formulary tier. Tirosint prescribed for documented hypothyroidism (E03.x) with a normal TSH target is a separate clinical scenario and is the appropriate indication for coverage requests.

The American Thyroid Association explicitly warns against using thyroid hormone therapy for weight loss in euthyroid patients, citing risks of cardiac arrhythmia, bone loss, and thyrotoxicosis [2]. No major payer, including Humana, covers thyroid hormone for this indication.

Using the Tirosint Manufacturer Savings Card with Humana

IBSA Pharma (Tirosint's manufacturer) offers a savings card for commercially insured patients that can reduce out-of-pocket costs significantly. Commercially insured patients may pay as little as $25, $35/month with the card, depending on the specific offer active at the time of enrollment.

The savings card cannot be used with any federal program, including Humana Medicare Advantage, Humana Part D, Medicaid, TRICARE, or any other government-funded plan. This is a federal anti-kickback statute requirement, not a Humana-specific restriction [14].

For commercially insured patients on Humana who receive a PA approval, stacking the manufacturer card with the plan benefit can reduce net cost substantially. The savings card is typically renewed annually and requires enrollment through the manufacturer's patient support program.

Patients without insurance coverage and without Medicare or Medicaid eligibility can access Tirosint at the cash price of approximately $230/month, or use GoodRx-type discount programs that may reduce that price at certain pharmacy chains, though discounts for branded gel-cap formulations are generally smaller than for generics.

IBSA's patient assistance program (PAP) provides free or reduced-cost Tirosint to patients who meet income eligibility criteria (typically at or below 400% of the federal poverty level) and who lack adequate insurance coverage. Applications are submitted through the IBSA patient support portal and require income documentation and a prescriber signature [15].

What to Do If Humana Denies Tirosint and You Cannot Afford Cash Pay

Four parallel actions can run simultaneously after a denial. First, submit the internal appeal with supporting lab data and peer-reviewed literature. Second, enroll in the manufacturer's PAP if income-eligible. Third, ask the prescribing physician to request a peer-to-peer review call with the Humana medical director, because peer-to-peer conversations overturn approximately 50% of initial PA denials in endocrinology, based on published utilization management data [16]. Fourth, contact your state insurance commissioner if the denial appears to violate state medical necessity or step therapy exception laws.

If the appeal ultimately fails on a commercial plan, two alternative formulations are worth discussing with the prescriber. Tirosint-SOL (levothyroxine sodium oral solution) has the same clinical rationale as the gel cap and a similar cost profile. Some Humana plans have different formulary placement for the liquid solution versus the gel cap, so checking both NDC codes is worthwhile.

Patients should also confirm that the pharmacy submitted the claim using the correct NDC and days-supply. Billing errors at the pharmacy level can generate a false denial that resolves with a simple resubmission.

TSH Monitoring After Starting Tirosint

Once Tirosint is approved and dispensed, TSH should be rechecked at 6 weeks after initiation or dose change, not sooner, because of levothyroxine's 7-day half-life and the pituitary's slower TSH response kinetics [4]. Rechecking at 4 weeks is common in clinical practice but may not fully reflect the steady-state TSH.

The Endocrine Society recommends annual TSH monitoring for stable hypothyroid patients on levothyroxine, with more frequent monitoring during pregnancy, after bariatric surgery, or when other medications are added that affect levothyroxine absorption [7]. Humana's PA approval for Tirosint may be contingent on documented annual lab monitoring, and lapsing on labs can complicate PA renewals.

TSH monitoring is covered under most Humana plans as a preventive or diagnostic lab service, often at $0 member cost under ACA preventive care rules when ordered for established hypothyroidism management [17]. Members should confirm lab network coverage before ordering to avoid out-of-network lab fees.

A TSH value drawn while the patient is switching from tablets to gel caps should be interpreted with caution during the first 6 weeks, because the transition period may show transient TSH fluctuation that does not reflect the final steady-state level. Clinicians should document this context clearly in the medical record and in any PA renewal submission.